LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Stock List・Organon & Co

Search

Organon & Co

Closed

SectorHealthcare

13.33 -0.07

Overview

Share price change

24h

Current

Min

13.28

Max

13.36

Key metrics
By Trading Economics
Income	351M 146M
Sales	-47M 1.5B
P/E Sector Avg	14.106 49.8
EPS	0.71
Dividend yield	0.6
Profit margin	10
Employees	10,000
EBITDA	286M 351M

Recommendations
By TipRanks
Recommendations	Sell
12 Months Forecast	-15.92% downside

Dividends
By Dow Jones
Dividend yield Sector Avg	0.60% 2.25%
Next Earnings	4 Aug 2026
Next Dividend date	11 Jun 2026
Next Ex Dividend date	11 May 2026

Market Stats
By TradingEconomics
Market Cap	26M 3.5B
Previous open	13.4
Previous close	13.33

News Sentiment

By Acuity

25%

75%

67 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

8.53 / 9.18 Support & Resistance

Organon & Co Chart

Past performance is not a reliable indicator of future results.

Related News

27 Apr 2026, 06:09 UTC

Acquisitions, Mergers, Takeovers

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27 Apr 2026, 02:33 UTC

Acquisitions, Mergers, Takeovers

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27 Apr 2026, 01:04 UTC

Acquisitions, Mergers, Takeovers

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7 Nov 2025, 14:41 UTC

Acquisitions, Mergers, Takeovers

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27 Apr 2026, 18:07 UTC

Acquisitions, Mergers, Takeovers

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27 Apr 2026, 15:14 UTC

Acquisitions, Mergers, Takeovers

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27 Apr 2026, 14:56 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 Apr 2026, 13:58 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 Apr 2026, 13:38 UTC

Hot Stocks

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27 Apr 2026, 12:18 UTC

Acquisitions, Mergers, Takeovers

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27 Apr 2026, 09:22 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27 Apr 2026, 00:38 UTC

Acquisitions, Mergers, Takeovers

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27 Apr 2026, 00:38 UTC

Acquisitions, Mergers, Takeovers

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24 Apr 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 17:09 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10 Apr 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 Apr 2026, 14:39 UTC

Acquisitions, Mergers, Takeovers

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 Apr 2026, 14:01 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 Apr 2026, 09:23 UTC

Hot Stocks

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Peer Comparison

Price change

Organon & Co Forecast

Price Target

By TipRanks

-15.92% downside

12 Months Forecast

Average 11.2 USD -15.92%

High 14 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forOrganon & Co - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

7 ratings

0

Buy

4

Hold

3

Sell

Based on 7 analysts giving stock ratings to Organon & Co - Dist in the past 3 months.

Technical Score

By Trading Central

8.53 / 9.18Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

There are no events.

Sentiment

By Acuity

67 / 347 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Other stocks from the sector

LLY

Eli Lilly and Co.

947.62

JNJ

Johnson and Johnson

221.12

ABBV

AbbVie Inc

201.14

UNH

UnitedHealth Group Inc

379.44

AZN

AstraZeneca PLC

182.32

Live chat